Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Alumis Inc. Common StockNASDAQ: ALMS

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income turns negative

Q2 FY2026 net income was -$142.22M, compared with $59.32M a year earlier. Trailing-twelve-month net income was -$438.96M. Over 3 fiscal years it compounded at +29.5% a year.

Context

  • Net income amounted to 1011.7% of revenue in FY2025.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of -$2.77B (+1036.6%) for the fiscal year ending Dec 2026, a step up from the -17.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$142.22M+52.8% QoQ
Last fiscal yearDec 2025
-$243.33M-17.3% YoY
LTMJun 2026
-$438.96M+92.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-339.7%-11.5%+328.2 pp
1 year-17.3%+1036.6%+1053.9 pp
3-year CAGR+29.5%+87.3%+57.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(243.33M) USD
Year-over-year change
+17.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +92.9% is the 3rd highest of 9, against a peer median of -27.2%.
  • Net income amounts to 5933.5% of revenue for ALMS, versus a peer median of 832.6%.
ALMS Competitors
Net Income for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$438.96M USD+92.9%+29.5%5933.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$364.23M USD+879.7%—121.5%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$87.07M USD+21.4%+12.6%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$84.74M USD-216.1%+23.4%143627.1%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M USD-46.5%-9.3%832.6%
IFRXInflaRx N.V.LTM Mar 2026€41.2M EUR-7.9%+14.1%140477.1%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$27.37M USD-52.6%-18.3%—
ANABAnaptysBio, Inc.LTM Mar 2026$26.79M USD-81.0%—11.5%
TLSATiziana Life Sciences LtdFY2025$18.43M USD+94.4%+13.7%—
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ALMS) —-27.2%+13.1%832.6%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Depreciation & Amortization250K1.28M3.15M3.5M
Deferred Income Tax000(8.56M)
Stock-Based Compensation5.96M8.63M19.46M43.52M
Change in Working Capital(1.92M)12.06M14.76M26.32M
Accounts Receivables0000
Inventory0000
Accounts Payables1.29M(642K)8.51M(6.04M)
Other Working Capital(3.21M)12.7M6.25M32.35M
Other Non-Cash Items(86K)3.05M1.79M(190.98M)
Operating Cash Flow(107.72M)(129.98M)(255.08M)(369.52M)
Capital Expenditures(2.41M)(4.5M)(1.73M)(653K)
Acquisitions (Net)0000
Purchases of Investments(209.08M)(11.28M)(240.06M)(209.17M)
Sales of Investments142.73M76.25M128M447.96M
Other Investing Activities00049.74M
Investing Cash Flow(68.75M)60.47M(113.79M)287.88M
Debt Repayment0000
Common Stock Issued00193.32M2.08M
Common Stock Repurchased000(17K)
Dividends Paid0000
Other Financing Activities1.73M(96K)40.59M0
Financing Cash Flow101.63M89.68M492.37M2.07M
Effect of Forex Changes0000
Net Change in Cash(74.85M)20.18M123.5M(79.58M)
Free Cash Flow(110.13M)(134.47M)(256.81M)(370.18M)

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.